source
- Schrödinger launches Tectora Therapeutics with $55 million Series A to target immunology and inflammationSchrödinger announced the formation of Tectora Therapeutics, a new biotech focused on immune‑mediated diseases, backed by a $55 million Series A financing round. As part of the launch, Schrödinger…
- Inhibrx reports promising responses to OX40 immunotherapy in HPV-positive head and neck cancerInhibrx announced that its experimental immunotherapy targeting the protein OX40 produced measurable responses in patients with head and neck cancer, with the clearest activity observed in a small…